These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 1482709

  • 1. A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma.
    Hum Gene Ther; 1992 Dec; 3(6):691-703. PubMed ID: 1482709
    [No Abstract] [Full Text] [Related]

  • 2. A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma.
    Hum Gene Ther; 1992 Dec; 3(6):677-90. PubMed ID: 1482708
    [No Abstract] [Full Text] [Related]

  • 3. Phase I study of cytokine-gene modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma.
    Hum Gene Ther; 1992 Dec; 3(6):665-76. PubMed ID: 1482707
    [No Abstract] [Full Text] [Related]

  • 4. Anti-tumor effects of interleukin 2 against renal cell carcinoma. In vitro study and clinical application.
    Marumo K, Tazaki H.
    Prog Clin Biol Res; 1990 Dec; 350():263-73. PubMed ID: 2117286
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Adoptive cellular therapy of renal carcinoma.
    West WH.
    Prog Clin Biol Res; 1989 Dec; 303():689-96. PubMed ID: 2789392
    [No Abstract] [Full Text] [Related]

  • 10. Interferon-alpha and interleukin-2 in the treatment of renal cell cancer.
    Holdener EE, Emmons RP, Brunda M, Evans L, Levitt D.
    Prog Clin Biol Res; 1990 Dec; 348():61-9. PubMed ID: 2201034
    [No Abstract] [Full Text] [Related]

  • 11. [Immunotherapy of metastatic renal cell cancer].
    Manseck A, Wirth M.
    Urologe A; 1993 Sep; 32(5):360-73. PubMed ID: 7692655
    [Abstract] [Full Text] [Related]

  • 12. HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer.
    Franzke A, Buer J, Probst-Kepper M, Lindig C, Framzle M, Schrader AJ, Ganser A, Atzpodien J.
    Cancer Biother Radiopharm; 2001 Oct; 16(5):401-9. PubMed ID: 11776757
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization].
    Pomer S, Thiele R, Staehler G, Drehmer I, Löhrke H, Schirrmacher V.
    Urologe A; 1995 May; 34(3):215-20. PubMed ID: 7610516
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids.
    Kugler A, Stuhler G, Walden P, Zöller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Müller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Müller GA, Ringert RH.
    Nat Med; 2000 Mar; 6(3):332-6. PubMed ID: 10700237
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.